Loading
Leads the COSS group and co-led EURAMOS-1, the largest osteosarcoma trial ever run.
Stefan Bielack (Stuttgart) chairs the Cooperative Osteosarcoma Study Group and was a lead investigator of EURAMOS-1, the 2,260-patient international trial showing that neither adding ifosfamide-etoposide for poor responders nor interferon for good responders improves outcomes over MAP chemotherapy, fixing MAP as the global standard. His COSS registry analyses define prognostic factors in osteosarcoma.
Shares the tags paediatric, cooperative-group.
Shares Osteosarcoma and the tag cooperative-group.
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.
Shares the tags paediatric, cooperative-group.
Shares Cytotoxic chemotherapy and the tag cooperative-group.
Shares Osteosarcoma and the tag cooperative-group.